Publications by authors named "N Zozaya"
Aims: Evaluate existing oncology value frameworks in terms of their methodology, structure, characteristics, and functionality using the example of enfortumab vedotin, an approved therapy for urothelial carcinoma.
Methods: A search of PubMed, grey literature, and official websites of relevant international organizations was performed from January 2022 to March 2023.
Results: Six frameworks were identified and analyzed, including the American Society of Clinical Oncology's assessment framework, European Society for Medical Oncology's Magnitude of Clinical Benefit Scale, the National Comprehensive Cancer Network's Evidence Blocks, Memorial Sloan Kettering Cancer Center's DrugAbacus, Institute for Clinical and Economic Review's assessment framework, and the Drug Assessment Framework.
Article Synopsis
- The study analyzes the cost-benefit of Spain's National Immunization Program (NIP) and an expanded version, focusing on the long-term benefits of vaccinating newborns over their lifetime.
- Using Excel for the analysis, the researchers estimated costs of €168.5 million for the 2020 NIP and €275.5 million for the expanded NIP, with potential economic benefits of €772.2 million and €803.0 million, respectively.
- The benefit-cost ratios were found to be €4.58 for the 2020 NIP and €2.91 for the expanded NIP, indicating that vaccination programs are an effective public health strategy that provides significant societal economic returns.
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
BMC Infect Dis
January 2024
Article Synopsis
- Respiratory syncytial virus (RSV) is a serious infectious disease with significant health, social, and economic impacts, prompting the need for effective preventive measures, such as the newly approved nirsevimab for infants.
- A novel multi-criteria decision analysis (MCDA) framework was developed to evaluate the effectiveness of nirsevimab compared to a placebo, incorporating insights from a panel of nine experts.
- The findings indicate that nirsevimab holds considerable value for RSV prevention in Spain, showcasing high efficacy, potential cost savings for healthcare, and promoting public health awareness while addressing health disparities.
Objectives: The aim of this study was to review the current evaluation and funding processes for new drugs in different developed countries, to provide a comparative framework with detailed, homogeneous, and up-to-date information.
Methods: Scientific publications, reports and websites were reviewed between July and December 2021 using PubMed, Google Scholar, and grey literature sources. The main items searched were actors and processes, including timelines, characteristics of clinical and economic evaluations, participation of stakeholders, elements of price and reimbursement decisions, cost-effectiveness thresholds and specific funds.
Background: In recent years, significant advances have been made in the field of rare diseases (RDs). However, there is a large number of RDs without specific treatment and half of these treatments have public funding in Spain. The aim of the FINEERR project was to carry out a multidisciplinary strategic discussion on the challenge of funding and access to RD-targeted drugs in Spain, in order to agree on specific proposals for medium-term improvement and hence support decision-making in the Spanish National Healthcare System (SNHS).
View Article and Find Full Text PDF